| pubmed-article:2807130 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2807130 | lifeskim:mentions | umls-concept:C1003377 | lld:lifeskim |
| pubmed-article:2807130 | lifeskim:mentions | umls-concept:C0031977 | lld:lifeskim |
| pubmed-article:2807130 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:2807130 | lifeskim:mentions | umls-concept:C0059932 | lld:lifeskim |
| pubmed-article:2807130 | lifeskim:mentions | umls-concept:C0871161 | lld:lifeskim |
| pubmed-article:2807130 | lifeskim:mentions | umls-concept:C0148398 | lld:lifeskim |
| pubmed-article:2807130 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:2807130 | pubmed:dateCreated | 1989-12-5 | lld:pubmed |
| pubmed-article:2807130 | pubmed:abstractText | The involvement of radical reactions in the ageing process, physiological as well as pathological, is well demonstrated. It is accepted that alloxan cyto-toxicity is linked to a production of hydroxylated free radicals and that a substance preventing the development of alloxanic diabetes possesses scavenger properties. The objective of this work was to demonstrate, in this model, the anti-radical effect of 3 molecules recommended in the treatment of cerebral insufficiency and a reference substance (+)-catechin. We observed a protective action with catechin (P less than 0.05) at the highest dose (100 mg/kg). PEG alone was moderately active but comparison of PEG-alloxan and PEG-exifone-alloxan showed a highly significant difference (P less than 0.001) at the two highest doses (60 and 120 mg/kg). Piracetam (200 and 400 mg/kg) and vinburnine (7.5 and 15 mg/kg) were inactive. Under these experimental conditions, exifone demonstrated remarkable anti-radical properties. | lld:pubmed |
| pubmed-article:2807130 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2807130 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2807130 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2807130 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2807130 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2807130 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2807130 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2807130 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2807130 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2807130 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2807130 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2807130 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2807130 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2807130 | pubmed:issn | 0767-3981 | lld:pubmed |
| pubmed-article:2807130 | pubmed:author | pubmed-author:PappSS | lld:pubmed |
| pubmed-article:2807130 | pubmed:author | pubmed-author:AllainHH | lld:pubmed |
| pubmed-article:2807130 | pubmed:author | pubmed-author:Van den... | lld:pubmed |
| pubmed-article:2807130 | pubmed:author | pubmed-author:ReymannJ MJM | lld:pubmed |
| pubmed-article:2807130 | pubmed:author | pubmed-author:Bentue-Ferrer... | lld:pubmed |
| pubmed-article:2807130 | pubmed:author | pubmed-author:PhilouzeVV | lld:pubmed |
| pubmed-article:2807130 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2807130 | pubmed:volume | 3 | lld:pubmed |
| pubmed-article:2807130 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2807130 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2807130 | pubmed:pagination | 323-8 | lld:pubmed |
| pubmed-article:2807130 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:2807130 | pubmed:meshHeading | pubmed-meshheading:2807130-... | lld:pubmed |
| pubmed-article:2807130 | pubmed:meshHeading | pubmed-meshheading:2807130-... | lld:pubmed |
| pubmed-article:2807130 | pubmed:meshHeading | pubmed-meshheading:2807130-... | lld:pubmed |
| pubmed-article:2807130 | pubmed:meshHeading | pubmed-meshheading:2807130-... | lld:pubmed |
| pubmed-article:2807130 | pubmed:meshHeading | pubmed-meshheading:2807130-... | lld:pubmed |
| pubmed-article:2807130 | pubmed:meshHeading | pubmed-meshheading:2807130-... | lld:pubmed |
| pubmed-article:2807130 | pubmed:meshHeading | pubmed-meshheading:2807130-... | lld:pubmed |
| pubmed-article:2807130 | pubmed:meshHeading | pubmed-meshheading:2807130-... | lld:pubmed |
| pubmed-article:2807130 | pubmed:meshHeading | pubmed-meshheading:2807130-... | lld:pubmed |
| pubmed-article:2807130 | pubmed:meshHeading | pubmed-meshheading:2807130-... | lld:pubmed |
| pubmed-article:2807130 | pubmed:meshHeading | pubmed-meshheading:2807130-... | lld:pubmed |
| pubmed-article:2807130 | pubmed:meshHeading | pubmed-meshheading:2807130-... | lld:pubmed |
| pubmed-article:2807130 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2807130 | pubmed:articleTitle | Comparative evaluation of scavenger properties of exifone, piracetam and vinburnine. | lld:pubmed |
| pubmed-article:2807130 | pubmed:affiliation | Laboratory of Clinical and Experimental Pharmacology, Faculté de Médecine, Rennes, France. | lld:pubmed |
| pubmed-article:2807130 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2807130 | pubmed:publicationType | Comparative Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2807130 | lld:pubmed |
